文献速递垂体与肾上腺疾病

奥西洛司他相关肾上腺萎缩:ACTH依赖性库欣综合征病例系列

Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

CONTEXT: Medical therapy for Cushing's syndrome (CS) is increasingly used. A potent adrenal steroidogenesis inhibitor, osilodrostat, has been rarely linked to prolonged adrenal insufficiency (AI).…

要点

  • 奥西洛司他可致ACTH依赖性库欣综合征患者肾上腺体积显著缩小。
  • 肾上腺体积减少与奥西洛司他最大剂量正相关。
  • 肾上腺萎缩可伴或不伴肾上腺功能不全。

核心结论

  • 在部分ACTH依赖性库欣综合征患者中,奥西洛司他可诱导显著的肾上腺萎缩,伴或不伴肾上腺功能不全。

研究设计与样本

  • 非干预性、回顾性、纵向、经机构审查委员会批准的研究,纳入2000年1月1日至2025年7月1日在俄勒冈健康与科学大学治疗的库欣综合征患者。
  • 纳入标准为ACTH依赖性库欣综合征、接受奥西洛司他治疗>3个月、且有治疗前后CT图像可用于测量肾上腺体积。

主要发现

  • 奥西洛司他平均起始、最大和最终剂量分别为7.7、13.8和5.9 mg/日,疗程23个月。
  • 4例患者接受阻断-替代方案,5例发生肾上腺功能不全。

临床怎么用

  • 对接受奥西洛司他治疗的ACTH依赖性库欣综合征患者,应监测肾上腺功能不全。
  • 需更大规模研究在不同类型库欣综合征中进一步确认肾上腺萎缩现象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Medical therapy for Cushing's syndrome (CS) is increasingly used. A potent adrenal steroidogenesis inhibitor, osilodrostat, has been rarely linked to prolonged adrenal insufficiency (AI). OBJECTIVE: We hypothesized that osilodrostat-induced AI could be associated with adrenal gland shrinkage. DESIGN: Noninterventional, retrospective, longitudinal, institutional review board-approved study of patients with CS treated at Oregon Health and Science University between January 1, 2000, and July 1, 2025. SETTING: Ambulatory and inpatient, academic, quaternary medical center. PATIENTS OR OTHER PARTICIPANTS: Patients with ACTH-dependent CS, treated with osilodrostat for >3 months, and computed tomography (CT) imaging before and after osilodrostat available for adrenal volume (AV) measurement. INTERVENTION(S): Age, sex, osilodrostat doses and duration, laboratory data, and AI were recorded. AV was calculated using manual segmentation on CT images by a board-certified radiologist. MAIN OUTCOME MEASURE(S): AV before and after initiation of osilodrostat was expressed as percent reduction. RESULTS: Ten patients (5 ectopic CS, 4 unknown ACTH source, 1 Cushing's disease) were included. Osilodrostat mean starting, maximum, and final doses: 7.7, 13.8, and 5.9 mg/day, respectively, over 23 months. Four patients received block-and-replace regimen, AI developed in 5. Adrenal gland volume decreased by 46.7 ± 22.2% from 25.5 ± 9.9 mL to 12.7 ± 6.4 mL, P < .001 over a median of 19 months. AV reduction positively correlated with maximum osilodrostat dose, r = 0.626, P = .027. CONCLUSION: We found that in selected patients with ACTH-dependent CS, osilodrostat can induce significant adrenal shrinkage, with or without AI. Further confirmation by larger studies of different CS types and monitoring for AI is required for all patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Varlamov EV, Park BJ, Fleseriu M, et al. Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome. J Clin Endocrinol Metab. 2026. PMID: 41054820. doi:10.1210/clinem/dgaf552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。